ALX-1393 (TFA)
ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model[1].
Product Specifications
UNSPSC
12352005
Target
GlyT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/alx-1393-tfa.html
Concentration
10mM
Purity
99.83
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N[C@@H](COC(C1=CC=CC(F)=C1)C2=CC=CC=C2OCC3=CC=CC=C3)C(O)=O.OC(C(F)(F)F)=O
Molecular Formula
C25H23F4NO6
Molecular Weight
509.45
References & Citations
[1]Haranishi Y, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010 Feb 1;110 (2) :615-21.|[2]Takahashi Y, et al. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015 Mar;130:46-52.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6204360-01 0.1 mL
Bcl-X (Apoptosis regulator Bcl-X, B cell lymphoma 2 like, BCL XL/S, Bcl-2-like protein 1, Bcl2-L-1, BCL2L, Bcl2l1, BCLX, BclXL, BclXs, Protein phosphatase 1 regulatory subunit 52 (PPP1R52)) (BSA & Azide Free) (MaxLight 490)
Ask
View Details MBS6204360-02 5x 0.1 mL
Bcl-X (Apoptosis regulator Bcl-X, B cell lymphoma 2 like, BCL XL/S, Bcl-2-like protein 1, Bcl2-L-1, BCL2L, Bcl2l1, BCLX, BclXL, BclXs, Protein phosphatase 1 regulatory subunit 52 (PPP1R52)) (BSA & Azide Free) (MaxLight 490)
Ask
View Details